Document is current

Article History

Received: 11 June 2024

Accepted: 4 February 2025

First Online: 18 February 2025

Declarations

:

: Trial registration: Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders (BipoLife-A1), NCT02456545, Registered at 11 May 2015, .

: Not applicable.

: PFP is supported by #NEXTGENERATIONEU (NGEU), funded by the Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006) – A Multiscale integrated approach to the study of the nervous system in health and disease (DN. 1553 11.10.2022). CB, MB, AP and PFP have received funding from the German Research Foundation (DFG) grant number GRK2773/1 – 454245598. MB has additionally received funding from Bundesministerium für Bildung und Forschung, and the European Commission. He served as a consultant to GH Research, Janssen-Cilag, neuraxpharm, Novartis, Shire International, Sunovion, and Takeda, and received fees from Aristo, Hexal, Janssen Cilag, and Sunovion. AR serves on advisory boards and receives speaker’s honoraria from Medice, Shire/ Takeda, Janssen, neuraxpharm, Servier and SAGE. SKS has received speaker’s honoraria from Taked, Medice and Janssen in the past 3 years. CU Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, J. Martini et al. European Neuropsychopharmacology 78 (2024) 43–53 52 MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. All other authors state to have no conflict of interest.